Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA5 in Antiphospholipid Syndrome (APS) and Recurrent Thrombosis
NCT07632976Phase 1Active, not recruiting
- Sponsor
- Lan-Yi Therapeutics
- Start
- May 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of EA5 in antiphospholipid syndrome (APS) and thrombosis (2 cohorts), sponsored by Lan-Yi Therapeutics. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at Week 28. Started May 2026; status: active, not recruiting.
02
Drugs
EA5
03
Conditions
antiphospholipid syndrome (APS)thrombosis
Beyond the preview
Go deeper on NCT07632976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632976.